Moisture Chamber Glasses for Dry Eye in Asian Population
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01388426 |
Recruitment Status
:
Completed
First Posted
: July 6, 2011
Last Update Posted
: January 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dry Eye | Device: 7eye( Panoptx)™ moisture chamber glasses | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Moisture Chamber Glasses for Dry Eye in Asian Population |
Study Start Date : | July 2011 |
Actual Primary Completion Date : | August 2012 |
Actual Study Completion Date : | August 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: 7eye( Panoptx)™ Moisture chamber glasses
7eye( Panoptx)™
|
Device: 7eye( Panoptx)™ moisture chamber glasses
moisture chamber glasses
Other Name: 7eye™
|
- Percentage of time wearing moisture chamber glasses while outdoors during 2 weeks of the study. [ Time Frame: 2 weeks during 3 months ]
- 1.Number of eyedrops per day for each type of medication used at the end of study vs at the commencement of study,symptoms of dry eye (using the VAS),corneal fluorescence staining and tear break up time(TBUT). [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. Subjects with evaporative dry eye as assessed by the PI in the dry eye clinic and has occupational or lifestyle requirement to be exposed to a hyper-evaporative environment.
Exclusion Criteria:
- Subjects who can't wear the eye wear as instructed in the study, or unable to complete the diary of eye wear use.
- Subjects with eye lid or facial bone malformation
- Subjects with a significant refractive error that warrants spectacles with a refractive power.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388426
Singapore | |
Singapore National Eye Center | |
Singapore, Singapore, 168751 | |
Singapore National Eye Centre | |
Singapore, Singapore, 168751 |
Principal Investigator: | Samanthila Waduthantri | Singapore National Eye Centre | |
Principal Investigator: | Louis Tong | Singapore National Eye Centre | |
Study Chair: | Chien Hua Tan | Singapore National Eye Centre |
Responsible Party: | Samanthila Waduthantri, Clinical Research Fellow, Clinical Associate, Singapore National Eye Centre |
ClinicalTrials.gov Identifier: | NCT01388426 History of Changes |
Other Study ID Numbers: |
R746 |
First Posted: | July 6, 2011 Key Record Dates |
Last Update Posted: | January 10, 2013 |
Last Verified: | January 2013 |
Additional relevant MeSH terms:
Keratoconjunctivitis Sicca Dry Eye Syndromes Keratoconjunctivitis Conjunctivitis Conjunctival Diseases Eye Diseases Keratitis Corneal Diseases Lacrimal Apparatus Diseases Methamphetamine Central Nervous System Stimulants Physiological Effects of Drugs |
Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Dopamine Uptake Inhibitors |